Jacobio Pharmaceuticals Strengthens Growth Confidence
Jacobio Pharmaceuticals (1167.HK) has made headlines with a bold investment decision by its Chairman and CEO, Dr. Yinxiang Wang. Along with concerted parties, they have increased their shareholding in the company by 11.06 million shares, totaling an investment of around HK$96.34 million. This significant share purchase not only highlights their confidence in the company's future but also indicates a strong belief in its long-term growth potential.
Share Repurchase Plan and Investment Strategy
The company's proactive share repurchase plan, approved by the Board, has an upper limit of HK$100 million. So far, Jacobio has successfully repurchased 326,400 shares, spending approximately HK$2.67 million. This initiative demonstrates the management's commitment to enhancing shareholder value, and they intend to continue the share repurchase based on current market conditions, signaling confidence to investors and market watchers alike.
Research and Development Achievements
Jacobio's recent interim results have showcased impressive R&D advancements. The company is focusing on two significant areas: KRAS and iADC. With ongoing progress in these core programs, Jacobio is solidifying its competitive edge and growth potential within the dynamic global biopharmaceutical landscape.
Groundbreaking KRAS Developments
A key highlight in Jacobio's KRAS pathway is the approval of Glecirasib, a KRAS G12C inhibitor, which recently received clearance from the National Medical Products Administration (NMPA) for second-line treatment of KRAS G12C mutant non-small cell lung cancer (NSCLC). The launch of Glecirasib in China marks a pivotal moment for Jacobio, notably because it not only represents their entry into the commercial market but also triggers a milestone payment from their partner, Allist, amounting to RMB 50 million. In combination therapy, Glecirasib is being evaluated alongside the SHP2 inhibitor sitneprotafib for first-line NSCLC patients.
Progress in Pan-KRAS Inhibitor Trials
Another promising asset is JAB-23E73, Jacobio's pan-KRAS inhibitor, which is currently in the dose-escalation phase of its Phase I trial. Here, several confirmed partial responses (PRs) have been reported, alongside favorable safety and pharmacokinetic profiles. The full clinical data from this trial is expected to be released next year, representing a critical milestone in advancing the global pan-KRAS treatment landscape.
Innovative iADC Drug Development
Additionally, Jacobio is pushing boundaries with its innovative iADC projects. Leading the way is JAB-BX467, a HER2-STING iADC candidate designed to transform “cold tumors” into “hot tumors,” revolutionizing how certain solid tumors are treated where PD-1 monotherapy has shown limited efficacy. Currently, this program is in the preclinical stage, with plans to submit an IND application in the latter half of next year.
Vision of Long-term Success
As an innovation-driven company, Jacobio is carving out its place among global leaders in KRAS and iADC research, backed by a robust development strategy and substantial commercial opportunities. The management firmly believes that the current share price does not accurately reflect the true value of their diverse pipeline nor their long-term growth potential. The Chairman's recent decision to increase shareholding serves as a strong signal of commitment to creating ongoing value for investors.
About Jacobio Pharma
Jacobio Pharma (1167.HK) is dedicated to developing progressive treatments for patients facing serious health challenges. It operates an allosteric drug discovery platform targeting the KRAS pathway and is ambitious about becoming a leading entity in global research and development. The company nurtures strategic collaborations to enhance innovation and drive improvements in patient outcomes. Jacobio's research and development facilities are positioned in urban centers such as Beijing, Shanghai, and Boston, with extensive clinical trial operations spanning over 180 locations in China and additional sites in the USA and Europe.
Frequently Asked Questions
What recent investment has Jacobio Pharmaceuticals made?
Jacobio's Chairman and CEO, Dr. Yinxiang Wang, has increased shareholding by 11.06 million shares, investing HK$96.34 million.
What is the purpose of Jacobio's share repurchase plan?
The share repurchase plan aims to enhance shareholder value and demonstrate confidence in the Company’s long-term growth.
Which key areas is Jacobio focused on for research and development?
Jacobio is concentrating on KRAS and iADC, showing significant progress in both fields to enhance its competitiveness.
What was a significant milestone for Jacobio in KRAS therapy?
The approval and launch of Glecirasib for KRAS G12C mutant NSCLC marked an important entry into the Chinese market.
How is Jacobio innovating in cancer treatment development?
Through projects like JAB-BX467, Jacobio is working to improve treatment options for solid tumors by converting cold tumors into hot tumors.
